To the Editor:

We read with great interest the review of Ahn and Bomback[@bib1] describing the current diagnosis and management of podocytopathies. As underscored by the authors, the list of underlying processes associated with podocytopathies is growing. Infectious diseases are a major cause of podocytopathies, including collapsing glomerulopathy. We would like to emphasize 2 pathogens, *Plasmodium* species and SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; the causative agent of coronavirus disease 2019 \[COVID-19\]), which could be added to the spectrum of infectious agents associated with collapsing glomerulopathy.

We recently reported clinical and pathologic characteristics of 18 patients with collapsing glomerulopathy occurring within 3 months of an acute malaria episode.[@bib2] Interestingly, all 7 tested patients had high-risk variants of *APOL1.* As discussed by Anh and Bomback, infection caused by *Plasmodium* species may act as a second hit leading to collapsing glomerulopathy in genetically predisposed patients*.* Similarly, compelling evidence suggests that SARS-CoV-2 may act as a trigger for collapsing glomerulopathy occurrence in patients of African ancestry and genetic susceptibility factors.[@bib3] Whether SARS-CoV-2--associated collapsing glomerulopathy is the result of direct podocyte viral infection or may be related to secondary mechanisms remains to be determined.[@bib3] Further studies (including genotyping of *APOL1*) will decipher the role of genetic predisposition in the pathogenesis of this secondary form of collapsing glomerulopathy.

These findings suggest that malaria and COVID-19 may be 2 additional infectious diseases leading to toxic podocytopathies.
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